Beta Amyloid News and Research

RSS

Weill Cornell reports new findings from IVIG Phase 3 trial in Alzheimer's disease at AAIC 2013

Weill Cornell Medical College neurologist Dr. Norman Relkin reported new findings today from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease at the Alzheimer's Association International Conference in Boston, Mass.

16 Jul 2013

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

Eli Lilly and Company today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a draft decision proposing Coverage with Evidence Development for the use of beta-amyloid positron emission tomography (PET) imaging agents. Beta-amyloid imaging agents are used to evaluate patients with cognitive impairment for Alzheimer's Disease and other causes of cognitive decline.

5 Jul 2013

Caspase-2 protein contributes to cognitive decline associated with Alzheimer's disease

Researchers at Columbia University Medical Center have demonstrated that a protein called caspase-2 is a key regulator of a signaling pathway that leads to cognitive decline in Alzheimer's disease.

26 Jun 2013

Lipidation states in certain proteins in the brain differ depending on genotype, cognitive diseases

The lipidation states (or modifications) in certain proteins in the brain that are related to the development of Alzheimer disease appear to differ depending on genotype and cognitive diseases, and levels of these protein and peptides appear to be influenced by diet, according to a report published Online First by JAMA Neurology, a JAMA Network publication.

19 Jun 2013

Common medications reduce brain plaques in mice

Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One.

13 Jun 2013

Elderly patients exposed to general anaesthesia face increased risk of developing dementia

Exposure to general anaesthesia increases the risk of dementia in the elderly by 35%, says new research presented at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology (ESA). The research is by Dr Francois Sztark, INSERM and University of Bordeaux, France, and colleagues.

1 Jun 2013

Cognoptix' SAPPHIRE II eye test identifies Alzheimer's disease patients via Ab signature in the eyes

Cognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes in a 10-subject proof-of-concept clinical trial.

23 May 2013

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

One of the biggest challenges with Alzheimer's disease (AD) is that by the time physicians can detect behavioral changes, the disease has already begun its irreversibly destructive course.

26 Apr 2013

Study sheds light on role of microglia during progression of Alzheimer's disease

The plaque deposits in the brain of Alzheimer's patients are surrounded by the brain's own immune cells, the microglia. This was already recognized by Alois Alzheimer more than one hundred years ago. But until today it still remains unclear what role microglia play in Alzheimer's disease.

12 Apr 2013

Cognoptix provides update on multi-site clinical trial of SAPPHIRE II eye test

Cognoptix announced today that it has reached the halfway point in a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes.

10 Apr 2013

New research shows surgical menopause increases cognitive decline and dementia

Women who abruptly and prematurely lose estrogen from surgical menopause have a two-fold increase in cognitive decline and dementia.

30 Mar 2013

Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.

28 Mar 2013

Researchers identify new substance in olive oil that reduces risk of Alzheimer's disease

The mystery of exactly how consumption of extra virgin olive oil helps reduce the risk of Alzheimer's disease (AD) may lie in one component of olive oil that helps shuttle the abnormal AD proteins out of the brain, scientists are reporting in a new study. It appears in the journal ACS Chemical Neuroscience.

21 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Amyloid plaques take about 15 years to build up and then plateau: Study

Researchers have identified a possible treatment window of several years for plaques in the brain that are thought to cause memory loss in diseases such as Alzheimer's. The Mayo Clinic study is published in the Feb. 27 online issue of Neurology, the medical journal of the American Academy of Neurology.

28 Feb 2013

Insight into how NMDA receptors function

In a pair of new papers, researchers at the University of California, San Diego School of Medicine and the Royal Netherlands Academy of Arts and Sciences upend a long-held view about the basic functioning of a key receptor molecule involved in signaling between neurons, and describe how a compound linked to Alzheimer's disease impacts that receptor and weakens synaptic connections between brain cells.

20 Feb 2013

TSG might be novel compound for treatment of Alzheimer's and dementia with Lewy body

Administration of the active compound tetrahydroxystilbene glucoside (TSG) derived from the Chinese herbal medicine Polygonum multiflorum Thunb, reversed both overexpression of α-synuclein, a small protein found in the brain, and its accumulation using a mouse model of Alzheimer's disease.

16 Feb 2013

Scientists receive honorary doctorate for research on Alzheimer's disease

On Monday 4 February, Dennis J. Selkoe and five other "brain teasers" will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate - VIB-KU Leuven professors Bart De Strooper and Wim Robberecht - will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer's Disease and other conditions that cause severe damage in the brain.

4 Feb 2013

Medicare expands competitive bidding program

The new prices will kick in July 1 and are expected to save on average 45 percent for products such as walkers, wheelchairs, oxygen equipment and other medical products.

2 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013